重组人脑利钠肽联合左西孟旦治疗重症脓毒症心肌病患者的效果及对LVEF、LVEDD水平的影响  

The effect of recombinant human brain natriuretic peptide combined with levosimendan in patients with severe septic cardiomyopathy and its influence on LVEF and LVEDD levels

作　　者：许彬彬 XU Bin-bin(Department of Critical Care Medicine,Yancheng First People's Hospital,Yancheng 224000,China)

机构地区：[1]盐城市第一人民医院重症医学科,224000

出　　处：《中国实用医药》2023年第21期102-105,共4页China Practical Medicine

摘　　要：目的探讨重症脓毒症心肌病患者选择重组人脑利钠肽联合左西孟旦的治疗效果及对患者心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)]水平的影响。方法100例重症脓毒症心肌病患者,运用单双数字表分组方式分为对照组和实验组,每组50例。对照组选择重组人脑利钠肽治疗,实验组在对照组基础上联合左西孟旦治疗。对比两组患者的治疗效果,治疗前后的LVEF、LVEDD水平,用药后不良反应发生情况。结果实验组治疗总有效率为96.00%,高于对照组的82.00%,差异具有统计学意义(P<0.05)。实验组治疗前、治疗后24 h、治疗后48 h、治疗后72 h的LVEF分别为(31.37±4.13)%、(42.63±5.05)%、(43.22±5.88)%、(55.37±5.03)%,对照组分别为(31.22±4.03)%、(31.28±4.05)%、(36.63±3.23)%、(42.63±5.05)%。实验组治疗前、治疗后24 h、治疗后48 h、治疗后72 h的LVEDD分别为(62.52±4.13)、(60.28±2.05)、(55.13±0.32)、(50.28±4.05)mm,对照组分别为(62.33±4.05)、(60.32±2.05)、(55.28±4.05)、(51.28±3.05)mm。实验组治疗后24、48、72 h的LVEF均高于本组治疗前,对照组治疗后48、72 h的LVEF均高于本组治疗前,差异具有统计学意义(P<0.05)。两组治疗后24、48、72 h的LVEDD均小于本组治疗前,差异具有统计学意义(P<0.05)。实验组治疗后24、48、72 h的LVEF均高于对照组,差异具有统计学意义(P<0.05)。实验组用药后的不良反应发生率为4.00%,低于对照组的16.00%,差异具有统计学意义(P<0.05)。结论重症脓毒症心肌病患者选择重组人脑利钠肽联合左西孟旦治疗可显著改善患者的心脏参数,降低药物不良反应发生率,提升疾病治疗效果。Objective To discuss the effect of recombinant human brain natriuretic peptide combined with levosimendan in patients with severe septic cardiomyopathy and its influence on left ventricular ejection fraction(LVEF)and left ventricular end diastolic diameter(LVEDD)levels.Methods A total of 100 patients with severe septic cardiomyopathy were divided into control group and experimental group according to oddeven numerical table,with 50 cases in each group.The control group was treated with recombinant human brain natriuretic peptide,and the experimental group was treated with levosimendan based on the control group.The therapeutic effect,LVEF and LVEDD levels before and after treatment,and the occurrence of adverse reactions after medication were compared between the two groups.Results The total effective rate of the experimental group was 96.00%,which was higher than that of 82.00%of the control group,and the difference was statistically significant(P<0.05).Before treatment,24 h after treatment,48 h after treatment and 72 h after treatment,LVEF were(31.37±4.13)%,(42.63±5.05)%,(43.22±5.88)%and(55.37±5.03)%in the experimental group,and were(31.22±4.03)%,(31.28±4.05)%,(36.63±3.23)%and(42.63±5.05)%in the control group.Before treatment,24 h after treatment,48 h after treatment and 72 h after treatment,LVEDD were(62.52±4.13),(60.28±2.05),(55.13±0.32)and(50.28±4.05)mm in the experimental group,and were(62.33±4.05),(60.32±2.05),(55.28±4.05)and(51.28±3.05)mm in the control group.LVEF at 24,48 and 72 h after treatment in the experimental group was higher than those before treatment in this group;LVEF at 48 and 72 h after treatment in the control group was higher than those before treatment in this group;the difference were statistically significant(P<0.05).LVEDD at 24,48 and 72 h after treatment in both groups was lower than those before treatment in this group,and the differences were statistically significant(P<0.05).LVEF of the experimental group at 24,48 and 72 h after treatment was higher than those of th

关 键 词：重组人脑利钠肽 左西孟旦 重症脓毒症心肌病 左心室射血分数 左心室舒张末期内径 

分 类 号：R459.7[医药卫生—急诊医学] R542.2[医药卫生—治疗学]